Singapore markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
39.34-1.00 (-2.48%)
At close: 04:00PM EDT
39.34 0.00 (0.00%)
After hours: 04:11PM EDT
Show:
Income statement
Cash flow
Annual

Balance sheet

All numbers in thousands
Breakdown
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Assets
Current assets
Cash
Cash and cash equivalents
213,584
132,944
307,584
713,526
-
Other short-term investments
363,625
614,818
432,612
488,007
-
Total cash
577,209
747,762
740,196
1,201,533
-
Net receivables
73,390
40,445
28,432
23,093
-
Inventory
33,969
26,766
16,231
13,048
-
Other current assets
47,616
68,926
71,745
-
-
Total current assets
732,184
883,899
856,604
1,295,304
-
Non-current assets
Property, plant and equipment
Gross property, plant and equipment
373,967
323,107
226,221
151,431
-
Accumulated depreciation
-83,401
-63,381
-50,038
-37,392
-
Net property, plant and equipment
290,566
259,726
176,183
114,039
-
Equity and other investments
199,901
148,970
293,858
165,881
-
Goodwill
44,406
44,406
44,406
44,406
-
Intangible assets
166,271
160,105
130,788
131,113
-
Other long-term assets
57,685
48,338
20,558
8,812
-
Total non-current assets
758,829
661,545
665,793
464,251
-
Total assets
1,491,013
1,545,444
1,522,397
1,759,555
-
Liabilities and stockholders' equity
Liabilities
Current liabilities
Accounts payable
42,114
43,274
17,138
12,923
-
Accrued liabilities
196,486
204,678
145,555
108,491
-
Deferred revenues
0
1,479
7,609
59,219
-
Other current liabilities
29,242
-
-
-
-
Total current liabilities
280,437
261,210
181,368
189,609
-
Non-current liabilities
Deferred tax liabilities
30,058
31,667
33,306
33,306
-
Deferred revenues
-
0
1,467
7,349
0
Other long-term liabilities
12,205
4,820
1,005
-
-
Total non-current liabilities
935,162
931,740
418,468
415,571
-
Total liabilities
1,215,599
1,192,950
599,836
605,180
-
Stockholders' equity
Common stock
82
70
69
67
-
Retained earnings
-3,387,661
-2,781,022
-2,073,601
-1,619,576
-
Accumulated other comprehensive income
647
-6,573
-1,404
689
-
Total stockholders' equity
275,414
352,494
922,561
1,154,375
-
Total liabilities and stockholders' equity
1,491,013
1,545,444
1,522,397
1,759,555
-